

# Pierluigi Navarra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4513935/publications.pdf>

Version: 2024-02-01

62  
papers

1,025  
citations

516561

16  
h-index

477173

29  
g-index

63  
all docs

63  
docs citations

63  
times ranked

1725  
citing authors

#	ARTICLE	IF	CITATIONS
1	Extended-release calcifediol in stage 3&#x2013;4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D. <i>Journal of Nephrology</i> , 2022, 35, 863-873.	0.9	10
2	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. <i>Pharmacological Research</i> , 2022, 175, 105997.	3.1	43
3	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. <i>Experientia Supplementum (2012)</i> , 2022, 113, 295-350.	0.5	3
4	The effects of CHF6467, a new mutated form of NGF, on cell models of human glioblastoma. A comparison with wild-type NGF. <i>Growth Factors</i> , 2022, 40, 37-45.	0.5	2
5	Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	1
6	Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 810-819.	1.0	11
7	Kinetics of Intestinal Presence of Spores Following Oral Administration of <i>Bacillus clausii</i> Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 375-384.	0.6	1
8	Cell-of-Origin and Genetic, Epigenetic, and Microenvironmental Factors Contribute to the Intra-Tumoral Heterogeneity of Pediatric Intracranial Ependymoma. <i>Cancers</i> , 2021, 13, 6100.	1.7	4
9	Beyond antibodies: ankyrins and DARPins. From basic research to drug approval. <i>Current Opinion in Pharmacology</i> , 2020, 51, 93-101.	1.7	16
10	Development of an UPLC-MS/MS Method for Quantitative Analysis of Clotrimazole in Human Plasma Samples. <i>Separations</i> , 2020, 7, 62.	1.1	1
11	A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB. <i>Journal of Headache and Pain</i> , 2020, 21, 124.	2.5	7
12	PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8214.	1.8	25
13	Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8242.	1.8	82
14	P2X7 receptors exert a permissive effect on the activation of presynaptic AMPA receptors in rat trigeminal caudal nucleus glutamatergic nerve terminals. <i>Journal of Headache and Pain</i> , 2020, 21, 83.	2.5	12
15	DNA inhibitors for the treatment of brain tumors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 195-207.	1.5	3
16	A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1083-1092.	0.8	11
17	Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. <i>Annals of Intensive Care</i> , 2020, 10, 94.	2.2	36
18	Vascular endothelial growth factor receptor 1 in glioblastoma-associated microglia/macrophages. <i>Oncology Reports</i> , 2020, 43, 2083-2092.	1.2	10

#	ARTICLE	IF	CITATIONS
19	Tigecycline pharmacokinetics in critically ill patients on renal replacement therapy: possible warnings and potential perspectives for the research agenda. <i>Annals of Intensive Care</i> , 2020, 10, 141.	2.2	1
20	Aspirin inhibits proliferation and promotes differentiation of neuroblastoma cells via p21 Waf1 protein up-regulation and Rb1 pathway modulation. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 7078-7087.	1.6	9
21	When innovation goes fast. The case of hemophilia. <i>Current Opinion in Pharmacology</i> , 2019, 45, 95-101.	1.7	5
22	Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation. <i>Journal of Cellular Physiology</i> , 2019, 234, 15459-15471.	2.0	19
23	Phospho-mTOR expression in human glioblastoma microglia-macrophage cells. <i>Neurochemistry International</i> , 2019, 129, 104485.	1.9	17
24	Pro-Inflammatory Activation of a New Immortalized Human Microglia Cell Line. <i>Brain Sciences</i> , 2019, 9, 111.	1.1	21
25	Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis. <i>Peptides</i> , 2019, 116, 16-21.	1.2	22
26	Optimizing Patient Selection to Maximize Drug Efficacy: the Expanding Role of Pharmacogenomics in the Clinical Development of Pembrolizumab for the Treatment of Non-small Cell Lung Cancer. <i>Clinical Therapeutics</i> , 2019, 41, 982-991.	1.1	1
27	Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation. , 2019, 234, 15459.		1
28	The mTOR kinase inhibitor rapamycin enhances the expression and release of pro-inflammatory cytokine interleukin 6 modulating the activation of human microglial cells. <i>EXCLI Journal</i> , 2019, 18, 779-798.	0.5	12
29	The process of drug discovery and the Yin/Yang of small-molecule/biotech option. <i>Microchemical Journal</i> , 2018, 136, 139-142.	2.3	0
30	Perampanel inhibits calcitonin gene-related peptide release from rat brainstem in vitro. <i>Journal of Headache and Pain</i> , 2018, 19, 107.	2.5	15
31	Authors'™ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®. <i>Neurology and Therapy</i> , 2018, 7, 391-393.	1.4	0
32	The human microglial HMC3 cell line: where do we stand? A systematic literature review. <i>Journal of Neuroinflammation</i> , 2018, 15, 259.	3.1	138
33	Diffusion of complementary evolving pharmaceutical innovations: The case of Abacavir and its pharmacogenetic companion diagnostic in Italy. <i>Technological Forecasting and Social Change</i> , 2018, 134, 223-233.	6.2	5
34	Interactions between integrase inhibitors and human arginase 1. <i>Journal of Neurochemistry</i> , 2017, 142, 153-159.	2.1	4
35	Blockade of CCR5 receptor prevents M2 microglia phenotype in a microglia-glioma paradigm. <i>Neurochemistry International</i> , 2017, 108, 100-108.	1.9	43
36	The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 106.	3.5	36

#	ARTICLE	IF	CITATIONS
37	A Comprehensive Review on Copemyl <sup>®</sup> . <i>Neurology and Therapy</i> , 2017, 6, 161-173.	1.4	6
38	PP077 Intravitreal Corticosteroids In Macular Edema: Quality Of The Evidence. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 107-108.	0.2	0
39	Optimal Solubility of Diclofenac <sup>®</sup> -Cyclodextrin in Combination with Local Anaesthetics for Mesotherapy Applications. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-8.	0.5	5
40	Corticosteroidi per via Intravitreale per il Trattamento Dell'edema Maculare: Revisione e Valutazione Della Qualit� Dell'evidenza. <i>Global &amp; Regional Health Technology Assessment</i> , 2017, 4, grhta.5000251.	0.2	0
41	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. <i>PLoS ONE</i> , 2017, 12, e0187393.	1.1	11
42	Exploiting Microglial Functions for the Treatment of Glioblastoma. <i>Current Cancer Drug Targets</i> , 2017, 17, 267-281.	0.8	40
43	Macrophages/microglia in glioblastoma: a Zelig-like story of changing phenotypes. <i>Translational Cancer Research</i> , 2017, 6, S1101-S1103.	0.4	0
44	mTOR in Multiple Sclerosis. , 2016, , 331-343.		5
45	Antiretrovirals inhibit arginase in human microglia. <i>Journal of Neurochemistry</i> , 2016, 136, 363-372.	2.1	15
46	Comparative Analysis of Real-Time Polymerase Chain Reaction Methods to Typing HLA-B*57:01 in HIV-1-Positive Patients. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 654-657.	0.5	7
47	Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection. <i>Infectious Diseases</i> , 2016, 48, 48-55.	1.4	5
48	First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing. <i>Journal of Clinical Virology</i> , 2016, 78, 1-3.	1.6	4
49	The analgesic agent tapentadol inhibits calcitonin gene-related peptide release from isolated rat brainstem via a serotonergic mechanism. <i>Life Sciences</i> , 2016, 145, 161-165.	2.0	8
50	mTOR Kinase: A Possible Pharmacological Target in the Management of Chronic Pain. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	54
51	The activation of type 1 corticotropin releasing factor receptor (CRF-R1) inhibits proliferation and promotes differentiation of neuroblastoma cells in vitro via p27Kip1 protein up-regulation and c-Myc mRNA down-regulation. <i>Molecular and Cellular Endocrinology</i> , 2015, 412, 205-215.	1.6	7
52	The free fractions of circulating docosahexaenoic acid and eicosapentenoic acid as optimal end-point of measure in bioavailability studies on n-3 fatty acids. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2015, 96, 11-16.	1.0	4
53	The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype. <i>Journal of Neuroinflammation</i> , 2014, 11, 125.	3.1	54
54	Proinflammatory-Activated Glioma Cells Induce a Switch in Microglial Polarization and Activation Status, From a Predominant M2b Phenotype to a Mixture of M1 and M2a/B Polarized Cells. <i>ASN Neuro</i> , 2014, 6, AN20130045.	1.5	67

#	ARTICLE	IF	CITATIONS
55	Antiretroviral agents increase NO production in gp120/IFN $\beta$ -stimulated cultures of rat microglia via an arginase-dependent mechanism. <i>Journal of Neuroimmunology</i> , 2014, 266, 24-32.	1.1	16
56	Tapentadol inhibits calcitonin gene-related peptide release from rat brainstem in vitro. <i>Peptides</i> , 2014, 56, 8-13.	1.2	9
57	Hydroxyurea induces vasopressin release and cytokine gene expression in the rat hypothalamus. <i>Journal of Neuroimmunology</i> , 2006, 179, 94-100.	1.1	2
58	Pharmacokinetics of Cyclosporin Microemulsion in Patients with Inflammatory Bowel Disease. <i>Clinical Pharmacokinetics</i> , 2001, 40, 473-483.	1.6	27
59	The Heme Oxygenase-Carbon Monoxide Pathway in the Control of Neuroendocrine Function. , 2001, 29, 108-116.		3
60	The Roles of Carbon Monoxide and Nitric Oxide in the Control of the Neuroendocrine Stress Response: Complementary or Redundant. <i>Stress</i> , 2001, 4, 3-11.	0.8	1
61	Endothelins Enhance Prostaglandin (PGE <sub>2</sub> and PGF <sub>2</sub> $\beta$ ) Biosynthesis and Release by Human Luteal Cells: Evidence of a New Paracrine/Autocrine Regulation of Luteal Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 811-817.	1.8	29
62	The Generation of Nitric Oxide and Carbon Monoxide Produces Opposite Effects on the Release of Immunoreactive Interleukin-1 $\beta$ from the Rat Hypothalamus in Vitro: Evidence for the Involvement of Different Signaling Pathways. <i>Endocrinology</i> , 1998, 139, 1031-1037.	1.4	19